Universe Pharmaceuticals INC
UPC
$4.91
-$0.21-4.10%
NASDAQ
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 23.02M | 24.88M | 26.73M | 29.52M | 32.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.02M | 24.88M | 26.73M | 29.52M | 32.31M |
| Cost of Revenue | 16.95M | 18.06M | 19.17M | 20.58M | 21.99M |
| Gross Profit | 6.07M | 6.81M | 7.56M | 8.94M | 10.32M |
| SG&A Expenses | 11.06M | 10.88M | 10.70M | 10.01M | 9.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1.40K | 18.80K | 36.20K | 66.30K | 96.40K |
| Total Operating Expenses | 31.04M | 31.81M | 32.58M | 34.43M | 36.27M |
| Operating Income | -8.02M | -6.94M | -5.86M | -4.91M | -3.97M |
| Income Before Tax | -8.12M | -12.57M | -17.02M | -10.68M | -4.33M |
| Income Tax Expenses | 606.80K | 1.28M | 1.94M | 2.10M | 2.25M |
| Earnings from Continuing Operations | -8.73 | -13.85 | -18.97 | -12.77 | -6.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.73M | -13.85M | -18.97M | -12.77M | -6.58M |
| EBIT | -8.02M | -6.94M | -5.86M | -4.91M | -3.97M |
| EBITDA | -7.53M | -6.44M | -5.36M | -4.41M | -3.46M |
| EPS Basic | 200.99 | 100.50 | -- | -- | -- |
| Normalized Basic EPS | -183.57 | -91.78 | -- | -- | -- |
| EPS Diluted | 200.99 | 100.50 | -- | -- | -- |
| Normalized Diluted EPS | -183.57 | -91.78 | -- | -- | -- |
| Average Basic Shares Outstanding | 43.60K | 21.80K | -- | -- | -- |
| Average Diluted Shares Outstanding | 43.60K | 21.80K | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |